Septerna vs Viking Therapeutics
SEPN and VKTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SEPN and VKTX compare
Viking Therapeutics is the larger company, worth 1.8 times as much as Septerna ($3.4B against $1.9B).
Septerna scores higher on the StockData Score (8 against 5 for Viking Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SEPN | VKTX |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $3.4B |
| Share price | $40.02 | $26.88 |
| Change, 1 year | 72.0% | −31.3% |
| Change, 5 years | – | 400% |
| Beta (5Y) | 0.70 | 1.24 |
| Employees | 130 | 53 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 19.4× | – |
| P/B | 4.4× (better) | 5.8× |
| FCF yield | −4.2% | – |
| Fair value | $15.08 | – |
| Margin of safety | −165% | – |
| Growth | ||
| Revenue growth (TTM) | 337% | – |
| Profitability | ||
| Operating margin | −76.2% | – |
| Net margin | −61.3% | – |
| FCF margin | −80.6% | – |
| Return on equity | −14.4% (better) | −96.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.84 | 7.27 (better) |
| Altman Z-score | 5.91 (better) | 2.25 |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 59.4% |
| Held by insiders | 27.9% | 2.7% |
| Insider net buying, 12 months | −$80.9M | −$18.2M (better) |
| Short interest, % of float | 10.0% | 19.5% |
Go deeper
- SEPN stock overview
- SEPN income statement
- SEPN valuation and score
- VKTX stock overview
- VKTX income statement
- VKTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.